Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep;128(10):1575-1584.
doi: 10.1111/1471-0528.16670. Epub 2021 Mar 22.

Early exposure of pregnant women to non-steroidal anti-inflammatory drugs delivered outside hospitals and preterm birth risk: nationwide cohort study

C Quantin  1   2   3   4   5 , C Yamdjieu Ngadeu  2   3 , J Cottenet  2   3 , S Escolano  1 , S Bechraoui-Quantin  2   3 , P Rozenberg  6   7 , P Tubert-Bitter #  1 , J-B Gouyon #  8
Affiliations

Early exposure of pregnant women to non-steroidal anti-inflammatory drugs delivered outside hospitals and preterm birth risk: nationwide cohort study

C Quantin et al. BJOG. 2021 Sep.

Abstract

Objective: To assess the risk of preterm birth associated with nonsteroidal anti-inflammatory drugs (NSAIDs), focusing on early exposure in the period from conception to 22 weeks of gestation (WG).

Design: National population-based retrospective cohort study.

Setting: The French National Health Insurance Database that includes hospital discharge data and health claims data.

Population: Singleton pregnancies (2012-2014) with a live birth occurring after 22WG from women between 15 and 45 years old and insured the year before the first day of gestation and during pregnancy were included. We excluded pregnancies for which anti-inflammatory medications were dispensed after 22WG.

Methods: The association between exposure and risk of preterm birth was evaluated with GEE models, adjusting on a large number of covariables, socio-demographic variables, maternal comorbidities, prescription drugs and pregnancy complications.

Main outcome measures: Prematurity, defined as a birth that occurred before 37WG.

Results: Among our 1 598 330 singleton pregnancies, early exposure to non-selective NSAIDs was associated with a significantly increased risk of preterm birth, regardless of the severity of prematurity: adjusted odds ratio (aOR) = 1.76 (95% CI 1.54-2.00) for extreme prematurity (95% CI 22-27WG), 1.28 (95% CI 1.17-1.40) for moderate prematurity (28-31WG) and 1.08 (95% CI 1.05-1.11) for late prematurity (32-36WG), with non-overlapping confidence intervals. We identified five NSAIDs for which the risk of premature birth was significantly increased: ketoprofen, flurbiprofen, nabumetone, etodolac and indomethacin: for the latter, aOR = 1.92 (95% CI 1.37-2.70) with aOR = 9.33 (95% CI 3.75-23.22) for extreme prematurity.

Conclusion: Overall, non-selective NSAID use (delivered outside hospitals) during the first 22WG was found to be associated with an increased risk of prematurity. However, the association differs among NSAIDs.

Tweetable abstract: French study for which early exposure to non-selective NSAIDs was associated with increased risk of prematurity.

Keywords: Early exposure; French National Health Insurance Database; non-steroidal anti-inflammatory drugs; risk of prematurity.

PubMed Disclaimer

Comment in

Similar articles

See all similar articles

Cited by

References

    1. Demailly R, Escolano S, Quantin C, Tubert‐Bitter P, Ahmed I. Prescription drug use during pregnancy in France: a study from the national health insurance permanent sample. Pharmacoepidemiol Drug Saf 2017;26:1126–34. - PubMed
    1. Research C for DE and FDA Drug Safety Communication: FDA has reviewed possible risks of pain medicine use during pregnancy. FDA [Internet]. 2 sept 201. Available at http://www.fda.gov/drugs/drug‐safety‐and‐availability/fda‐drug‐safety‐co... (accessed 10 September 2019).
    1. Agence nationale de sécurité du médicament et des produits de santé. Rappel sur la contre‐indication de tous les AINS à partir du début du 6ème mois de la grossesse ‐ Lettre aux professionnels de santé ‐ ANSM: Agence nationale de sécurité du médicament et des produits de santé [Internet]. Available at https://ansm.sante.fr/S‐informer/Informations‐de‐securite‐Lettres‐aux‐pr... (accessed 10 September 2019).
    1. Rappel: Jamais d’AINS à partir du début du 6ème mois de grossesse ‐ Point d’Information. ANSM : Agence nationale de sécurité du médicament et des produits de santé [Internet]. Available at https://ansm.sante.fr/S‐informer/Points‐d‐information‐Points‐d‐informati... (accessed 10 September 2019).
    1. Crespin S, Bourrel R, Hurault‐Delarue C, Lapeyre‐Mestre M, Montastruc JL, Damase‐Michel C. Drug prescribing before and during pregnancy in south west France: a retrolective study. Drug Saf 2011;34:595–604. - PubMed

Substances